Search

Your search keyword '"Emmett, Louise"' showing total 632 results
Start Over Author "Emmett, Louise"
632 results on '"Emmett, Louise"'

1. Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis

Author

Trapp, Christian, Aebersold, Daniel M., Belka, Claus, Casuscelli, Jozefina, Emmett, Louise, Eze, Chukwuka, Fanti, Stefano, Farolfi, Andrea, Fendler, Wolfgang, Grosu, Anca-Ligia, Guckenberger, Matthias, Hruby, George, Kirste, Simon, Koerber, Stefan A., Kroeze, Stephanie, Peeken, Jan C., Rogowski, Paul, Scharl, Sophia, Shelan, Mohamed, Spohn, Simon K. B., Strouthos, Iosif, Unterrainer, Lena, Vogel, Marco, Wiegel, Thomas, Zamboglou, Constantinos, and Schmidt-Hegemann, Nina-Sophie

Published
2024
Full Text
View/download PDF

2. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).

Author

Kratochwil, Clemens, Fendler, Wolfgang P, Eiber, Matthias, Hofman, Michael S, Emmett, Louise, Calais, Jeremie, Osborne, Joseph R, Iravani, Amir, Koo, Phillip, Lindenberg, Liza, Baum, Richard P, Bozkurt, Murat Fani, Delgado Bolton, Roberto C, Ezziddin, Samer, Forrer, Flavio, Hicks, Rodney J, Hope, Thomas A, Kabasakal, Levent, Konijnenberg, Mark, Kopka, Klaus, Lassmann, Michael, Mottaghy, Felix M, Oyen, Wim JG, Rahbar, Kambiz, Schoder, Heiko, Virgolini, Irene, Bodei, Lisa, Fanti, Stefano, Haberkorn, Uwe, and Hermann, Ken

Subjects
Humans, Lutetium, Heterocyclic Compounds, 1-Ring, Prostate-Specific Antigen, Dipeptides, Radiopharmaceuticals, Treatment Outcome, Nuclear Medicine, Male, Prostatic Neoplasms, Castration-Resistant, EANM/SNMMI, PSMA, [177Lu]Lu-PSMA-617, Aging, Urologic Diseases, Prostate Cancer, Cancer, Good Health and Well Being, EANM, SNMMI, [Lu-177]Lu-PSMA-617, Other Physical Sciences, Clinical Sciences, Nuclear Medicine & Medical Imaging
Abstract

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations of targeting molecules and radiolabels. Definitive evidence of the safety and efficacy of [177Lu]Lu-PSMA-617 in combination with standard-of-care has been demonstrated in patients with metastatic castration-resistant prostate cancer, whose disease had progressed after or during at least one taxane regimen and at least one novel androgen-axis drug. Preliminary data suggest that 177Lu-PSMA-radioligand therapy (RLT) also has high potential in additional clinical situations. Hence, the radiopharmaceuticals [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T are currently being evaluated in ongoing phase 3 trials. The purpose of this guideline is to assist nuclear medicine personnel, to select patients with highest potential to benefit from 177Lu-PSMA-RLT, to perform the procedure in accordance with current best practice, and to prepare for possible side effects and their clinical management. We also provide expert advice, to identify those clinical situations which may justify the off-label use of [177Lu]Lu-PSMA-617 or other emerging ligands on an individual patient basis.

Published
2023

3. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy

Author

Adebahr, Sonja, Althaus, Alexander, Scharl, Sophia, Strouthos, Iosif, Farolfi, Andrea, Serani, Francesca, Lanzafame, Helena, Trapp, Christian, Koerber, Stefan A., Peeken, Jan C., Vogel, Marco M. E., Vrachimis, Alexis, Spohn, Simon K. B., Grosu, Anca-Ligia, Kroeze, Stephanie G. C., Guckenberger, Matthias, Fanti, Stefano, Hruby, George, Emmett, Louise, Belka, Claus, Schmidt-Hegemann, Nina-Sophie, Henkenberens, Christoph, Aebersold, Daniel M., Wiegel, Thomas, Afshar-Oromieh, Ali, Zamboglou, Constantinos, and Shelan, Mohamed

Published
2024
Full Text
View/download PDF

4. The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis.

Author

Emmett, Louise, Papa, Nathan, Buteau, James, Ho, Bao, Liu, Victor, Roberts, Matthew, Thompson, James, Moon, Dan, Sheehan-Dare, Gemma, Alghazo, Omar, Agrawal, Shikha, Murphy, Declan, Stricker, Phillip, Hope, Thomas A, and Hofman, Michael S

Subjects
Cancer, Clinical Research, Urologic Diseases, Prostate Cancer, Biomedical Imaging, Clinical Trials and Supportive Activities, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Male, Humans, Prostate, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Magnetic Resonance Imaging, Prospective Studies, Gallium Radioisotopes, Pelvis, PSMA, prostate-specific membrane antigen, PET, multiparametricMRI, prostate cancer, diagnosis, multiparametric MRI, Clinical Sciences, Nuclear Medicine & Medical Imaging
Abstract

Multiparametric MRI (mpMRI) is validated for the diagnosis of clinically significant prostate cancer (csPCa). 68Ga-PSMA-11 PET/CT (68Ga-PSMA PET/CT) combined with mpMRI has improved negative predictive value over mpMRI alone for csPCa. The aim of this post hoc analysis of the PRIMARY study was to evaluate the clinical significance of patterns of intraprostatic PSMA activity, proposing a 5-point PRIMARY score to optimize the accuracy of 68Ga-PSMA PET/CT for csPCa in a low-prevalence population. Methods: The PRIMARY trial was a prospective multicenter phase II imaging trial that enrolled men with suspected PCa, no prior biopsy, and a recent mpMRI examination (6 mo) and for whom prostate biopsy was planned. In total, 291 men underwent mpMRI, 68Ga-PSMA PET/CT, and systematic biopsy with or without targeted biopsy. The mpMRI was read separately using the Prostate Imaging Reporting and Data System (PI-RADS) (version 2). 68Ga-PSMA PET/CT (pelvis only) was acquired a minimum of 60 min after injection. 68Ga-PSMA PET/CT was centrally read for pattern (diffuse transition zone [TZ], symmetric central zone [CZ], focal TZ, or focal peripheral zone [PZ]) and intensity (SUVmax). In this post hoc analysis, a 5-level PRIMARY score was assigned on the basis of analysis of the central read: no pattern (score of 1), diffuse TZ or CZ (not focal) (score of 2), focal TZ (score of 3), focal PZ (score of 4), or an SUVmax of at least 12 (score of 5). Two further readers independently assigned a PRIMARY score to 118 scans to determine interrater agreement. Associations between PRIMARY score and csPCa (International Society of Urological Pathology grade group ≥ 2) were evaluated. Results: Of the 291 men enrolled, 162 (56%) had csPCa. A PRIMARY score of 1 was present in 16% (47); a score of 2, in 19% (55); a score of 3, in 10% (29); a score of 4 in 40% (117); and a score of 5, in 15% (43). The proportion of patients with csPCa and a PRIMARY score of 1, 2, 3, 4, and 5 was 8.5% (4/47), 27% (15/55), 38% (11/29), 76% (89/117), and 100% (43/43), respectively. Sensitivity, specificity, positive predictive value, and negative predictive value for a PRIMARY score of 1 or 2 (low-risk patterns) versus a PRIMARY score of 3-5 (high-risk patterns) were 88%, 64%, 76%, and 81%, respectively, compared with 83%, 53%, 69%, and 72%, respectively, for a PI-RADS score of 2 versus 3-5 on mpMRI. The Cohen κ for a PRIMARY score of 1 of 2 versus a PRIMARY score of 3-5 was 0.76 (95% CI, 0.64-0.88) for reader 1 and 0.64 (95% CI, 0.49-0.78) for reader 2. Conclusion: A PRIMARY score incorporating intraprostatic pattern and intensity on 68Ga-PSMA PET/CT shows potential, with high diagnostic accuracy for csPCa. Further validation is warranted before implementation.

Published
2022

7. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer

Author

Buteau, James P., Moon, Daniel, Fahey, Michael T., Roberts, Matthew J., Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, De Abreu Lourenco, Richard, Dhillon, Haryana M., Kasivisvanathan, Veeru, Francis, Roslyn J., Stricker, Phillip, Agrawal, Shihka, O'Brien, Jonathan, McVey, Aoife, Sharma, Gaurav, Levy, Sidney, Ayati, Narjess, Nguyen, Andrew, Lee, Su-Faye, Pattison, David A., Sivaratnam, Dinesh, Frydenberg, Mark, Du, Yang, Titus, Jehan, Lee, Sze-Ting, Ischia, Joseph, Jack, Greg, Hofman, Michael S., and Emmett, Louise

Published
2024
Full Text
View/download PDF

8. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Author

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, and Davis, Ian D

Published
2024
Full Text
View/download PDF

9. European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy

Author

Scharl, Sophia, Zamboglou, Constantinos, Strouthos, Iosif, Farolfi, Andrea, Serani, Francesca, Koerber, Stefan A., Debus, Jürgen, Peeken, Jan C., Vogel, Marco M.E., Kroeze, Stephanie G.C., Guckenberger, Matthias, Krafcsik, Manuel, Hruby, George, Emmett, Louise, Schmidt-Hegemann, Nina-Sophie, Trapp, Christian, Spohn, Simon K.B., Henkenberens, Christoph, Mayer, Benjamin, Shelan, Mohamed, Aebersold, Daniel M., Thamm, Reinhard, and Wiegel, Thomas

Published
2024
Full Text
View/download PDF

10. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Author

Akhurst, Tim, Alipour, Ramin, Bailey, Dale, Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Crumbaker, Megan, Dhiantravan, Nattakorn, Hamid, Anis, Haskali, Mohammad, Hung, Terry, Kong, Grace, Lawrence, Nick, Lewin, Jeremy, McCarthy, Michael, Moodie, Kate, Murphy, Declan, Nguyen, Andrew, Pook, David, Ravi Kumar, Aravind, Roach, Paul, Roselt, Peter, Saghebi, Javad, Schembri, Geoff, Spain, Lavinia, Subramaniam, Shalini, Thang, Sue Ping, Thomas, Paul, Tran, Ben, Wallace, Roslyn, Yip, Sonia, Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G, Martin, Andrew J, and Davis, Ian D

Published
2024
Full Text
View/download PDF

11. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer

Author

Oprea-Lager, Daniela-Elena, MacLennan, Steven, Bjartell, Anders, Briganti, Alberto, Burger, Irene A., de Jong, Igle, De Santis, Maria, Eberlein, Uta, Emmett, Louise, Fizazi, Karim, Gillessen, Silke, Herrmann, Ken, Heskamp, Sandra, Iagaru, Andrei, Jereczek-Fossa, Barbara Alicja, Kunikowska, Jolanta, Lam, Marnix, Nanni, Cristina, O'Sullivan, Joe M., Panebianco, Valeria, Sala, Evis, Sathekge, Mike, Sosnowski, Roman, Tilki, Derya, Tombal, Bertrand, Treglia, Giorgio, Tunariu, Nina, Walz, Jochen, Yakar, Derya, Dierckx, Rudi, Sartor, Oliver, and Fanti, Stefano

Published
2024
Full Text
View/download PDF

13. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml

Author

Solomonidou, Nantia, Germanou, Daphnie, Strouthos, Iosif, Karagiannis, Efstratios, Farolfi, Andrea, Koerber, Stefan A., Debus, Juergen, Peeken, Jan C., Vogel, Marco E., Vrachimis, Alexis, Spohn, Simon K. B., Shelan, Mohamed, Aebersold, Daniel, Grosu, Anca-Ligia, Ceci, Francesco, Kroeze, Stephanie G. C., Guckenberger, Matthias, Fanti, Stefano, Belka, Claus, Hruby, George, Scharl, S., Wiegel, Thomas, Bartenstein, Peter, Henkenberens, Christoph, Emmett, Louise, Schmidt-Hegemann, Nina Sophie, Ferentinos, Konstantinos, and Zamboglou, Constantinos

Published
2023
Full Text
View/download PDF

15. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Author

Ceci, Francesco, Oprea-Lager, Daniela E, Emmett, Louise, Adam, Judit A, Bomanji, Jamshed, Czernin, Johannes, Eiber, Matthias, Haberkorn, Uwe, Hofman, Michael S, Hope, Thomas A, Kumar, Rakesh, Rowe, Steven P, Schwarzenboeck, Sarah M, Fanti, Stefano, and Herrmann, Ken

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Biomedical Imaging, Urologic Diseases, Prostate Cancer, Humans, Male, Nuclear Medicine, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Prostatic Neoplasms, Reproducibility of Results, PSMA-PET, PSMA prostate cancer, Structured report, Consensus panel, EANM guidelines, Prostate cancer guidelines, Other Physical Sciences, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

RationaleThe development of consensus guidelines for interpretation of Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide more consistent reports in clinical practice. The standardization of PSMA-PET interpretation may also contribute to increasing the data reproducibility within clinical trials. Finally, guidelines in PSMA-PET interpretation are needed to communicate the exact location of findings to referring physicians, to support clinician therapeutic management decisions.MethodsA panel of worldwide experts in PSMA-PET was established. Panelists were selected based on their expertise and publication record in the diagnosis or treatment of PCa, in their involvement in clinical guidelines and according to their expertise in the clinical application of radiolabeled PSMA inhibitors. Panelists were actively involved in all stages of a modified, nonanonymous, Delphi consensus process.ResultsAccording to the findings obtained by modified Delphi consensus process, panelist recommendations were implemented in a structured report for PSMA-PET.ConclusionsThe E-PSMA standardized reporting guidelines, a document supported by the European Association of Nuclear Medicine (EANM), provide consensus statements among a panel of experts in PSMA-PET imaging, to develop a structured report for PSMA-PET in prostate cancer and to harmonize diagnostic interpretation criteria.

Published
2021

16. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography

Author

Vis, André N., Meijer, Dennie, Roberts, Matthew J., Siriwardana, Amila R., Morton, Andrew, Yaxley, John W., Samaratunga, Hemamali, Emmett, Louise, van de Ven, Peter M., Heymans, Martijn W., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Boellaard, Thierry N., Schoots, Ivo G., Stricker, Phillip, Haynes, Anne-Maree, Oprea-Lager, Daniela E., Coughlin, Geoffrey D., and van Leeuwen, Pim J.

Published
2023
Full Text
View/download PDF

18. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy

Author

Kelly, Brian D., Ptasznik, Gideon, Roberts, Matthew J., Doan, Paul, Stricker, Phillip, Thompson, James, Buteau, James, Chen, Kenneth, Alghazo, Omar, O'Brien, Jonathan S., Hofman, Michael S., Frydenberg, Mark, Lawrentschuk, Nathan, Lundon, Dara, Murphy, Declan G., Emmett, Louise, and Moon, Daniel

Published
2023
Full Text
View/download PDF

19. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study

Author

Scharl, Sophia, Zamboglou, Constantinos, Strouthos, Iosif, Farolfi, Andrea, Serani, Francesca, Lanzafame, Helena, Giuseppe Morganti, Alessio, Trapp, Christian, Koerber, Stefan A., Debus, Jürgen, Peeken, Jan C., Vogel, Marco M.E., Vrachimis, Alexis, Spohn, Simon K.B., Ruf, Juri, Grosu, Anca-Ligia, Ceci, Francesco, Fendler, Wolfgang P., Bartenstein, Peter, Kroeze, Stephanie G.C., Guckenberger, Matthias, Krafcsik, Manuel, Klopscheck, Christina, Fanti, Stefano, Hruby, George, Emmett, Louise, Belka, Claus, Stief, Christian, Schmidt-Hegemann, Nina-Sophie, Henkenberens, Christoph, Mayer, Benjamin, Miksch, Jonathan, Shelan, Mohamed, Aebersold, Daniel M., Thamm, Reinhard, and Wiegel, Thomas

Published
2023
Full Text
View/download PDF

20. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Author

Seifert, Robert, Emmett, Louise, Rowe, Steven P., Herrmann, Ken, Hadaschik, Boris, Calais, Jeremie, Giesel, Frederik L., Reiter, Robert, Maurer, Tobias, Heck, Matthias, Gafita, Andrei, Morris, Michael J., Fanti, Stefano, Weber, Wolfgang A., Hope, Thomas A., Hofman, Michael S., Fendler, Wolfgang Peter, and Eiber, Matthias

Published
2023
Full Text
View/download PDF

22. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy

Author

Roberts, Matthew J., Morton, Andrew, Papa, Nathan, Franklin, Anthony, Raveenthiran, Sheliyan, Yaxley, William J., Coughlin, Geoffrey, Gianduzzo, Troy, Kua, Boon, McEwan, Louise, Wong, David, Delahunt, Brett, Egevad, Lars, Samaratunga, Hemamali, Brown, Nicholas, Parkinson, Robert, Emmett, Louise, and Yaxley, John W.

Published
2022
Full Text
View/download PDF

23. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

Author

Menzies, Alexander M., primary, Lo, Serigne N., additional, Saw, Robyn P.M., additional, Gonzalez, Maria, additional, Ch’ng, Sydney, additional, Nieweg, Omgo E., additional, Shannon, Kerwin F., additional, Ferguson, Peter M., additional, Lee, Jenny, additional, Emmett, Louise, additional, Kapoor, Rony, additional, Rawson, Robert V., additional, Stretch, Jonathan R., additional, Thompson, John F., additional, Spillane, Andrew J., additional, Rizos, Helen, additional, Scolyer, Richard A., additional, and Long, Georgina V., additional

Published
2024
Full Text
View/download PDF

24. Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial

Author

Gafita, Andrei, primary, Martin, Andrew J., additional, Emmett, Louise, additional, Eiber, Matthias, additional, Iravani, Amir, additional, Fendler, Wolfgang P., additional, Buteau, James, additional, Sandhu, Shahneen, additional, Azad, Arun A., additional, Herrmann, Ken, additional, Stockler, Martin R., additional, Davis, Ian D., additional, and Hofman, Michael S., additional

Published
2024
Full Text
View/download PDF

26. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

Author

Akhurst, Tim, Alipour, Ramin, Azad, Arun A, Banks, Patricia, Beaulieu, Alexis, Buteau, James P, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Kong, Grace, Kwan, Edmond M, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lewin, Jeremy, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Moodie, Kate, Murphy, Declan G, Ng, Siobhan, Pattison, David A, Pokorski, Izabella, Ramdave, Shakher, Ravi Kumar, Aravind S, Redfern, Andrew D, Rutherford, Natalie K, Saghebi, Javad, Sandhu, Shahneen, Scott, Andrew M, Spain, Lavinia, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Thang, Sue Ping, Tran, Ben, Wallace, Roslyn, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, and Zhang, Alison Y

Published
2022
Full Text
View/download PDF

27. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy

Author

Fanti, Stefano, Briganti, Alberto, Emmett, Louise, Fizazi, Karim, Gillessen, Silke, Goffin, Karolien, Hadaschik, Boris A., Herrmann, Ken, Kunikowska, Jolanta, Maurer, Tobias, MacLennan, Steven, Mottet, Nicolas, Murphy, Declan G., Oprea-Lager, Daniela E., O'Sullivan, Joe M., Oyen, Wim J.G., Rouvière, Olivier, Sartor, Oliver, Stenzl, Arnulf, Van Poppel, Hendrik, Walz, Jochen, Witjes, Wim, and Bjartell, Anders

Published
2022
Full Text
View/download PDF

28. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy

Author

Zamboglou, Constantinos, Strouthos, Iosif, Sahlmann, Joerg, Farolfi, Andrea, Serani, Francesca, Medici, Federica, Cavallini, Letizia, Morganti, Alessio Guiseppe, Trapp, Christian, Koerber, Stefan A., Peeken, Jan C., Vogel, Marco M.E., Schiller, Kilian, Combs, Stephanie E., Eiber, Matthias, Vrachimis, Alexis, Ferentinos, Konstantinos, Spohn, Simon K.B., Kirste, Simon, Gratzke, Christian, Ruf, Juri, Grosu, Anca-Ligia, Ceci, Francesco, Fendler, Wolfgang P., Miksch, Jonathan, Kroeze, Stephanie, Guckenberger, Matthias, Lanzafame, Helena, Fanti, Stefano, Hruby, George, Wiegel, Thomas, Emmett, Louise, Schmidt-Hegemann, Nina Sophie, and Henkenberens, Christoph

Published
2022
Full Text
View/download PDF

30. Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT.

Author

Li, Sherrington, Nguyen, Andrew, Counter, William, John, Nikeith C., De Leon, Jeremiah, Hruby, George, Joshua, Anthony M., Stricker, Phillip, Crumbaker, Megan, Ayati, Narjess, Lyn Chan, Sabahi, Zahra, Swiha, Mina, Kneebone, Andrew, Wong, Keith, Liu, Victor, Sharma, Shikha, Agrawal, Shikha, and Emmett, Louise M.

Published
2024
Full Text
View/download PDF

32. Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.

Author

Hope, Thomas A, Afshar-Oromieh, Ali, Eiber, Matthias, Emmett, Louise, Fendler, Wolfgang P, Lawhn-Heath, Courtney, and Rowe, Steven P

Subjects
Humans, Prostatic Neoplasms, Prostate-Specific Antigen, Magnetic Resonance Imaging, Neoplasm Staging, Patient Selection, Male, Multimodal Imaging, Biomarkers, Tumor, Positron Emission Tomography Computed Tomography, PET, PET/MRI, prostate cancer, prostate-specific membrane antigen, Cancer, Aging, Prostate Cancer, Bioengineering, Urologic Diseases, Biomedical Imaging, Clinical Sciences, Nuclear Medicine & Medical Imaging
Abstract

ObjectiveThe purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer.ConclusionPSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.

Published
2018

34. Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)

Author

Crumbaker, Megan, Pathmanandavel, Sarennya, Yam, Andrew O., Nguyen, Andrew, Ho, Bao, Chan, Lyn, Ende, Jesse A., Rofe, Christopher, Kongrak, Kamonwan, Kwan, Edmond M., Azad, Arun A., Sharma, Shikha, Pugh, Trevor J., Danesh, Arnavaz, Keane, Joanne, Eu, Peter, Joshua, Anthony M., and Emmett, Louise

Published
2021
Full Text
View/download PDF

42. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy

Author

Liu, Wei, Zukotynski, Katherine, Emmett, Louise, Chung, Hans T., Chung, Peter, Wolfson, Robert, Rachinsky, Irina, Kapoor, Anil, Metser, Ur, Loblaw, Andrew, Morton, Gerard, Sexton, Tracy, Lock, Michael, Helou, Joelle, Berlin, Alejandro, Boylan, Colm, Archer, Susan, Pond, Gregory R., and Bauman, Glenn

Published
2020
Full Text
View/download PDF

43. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer

Author

Buteau, James P., primary, Moon, Daniel, additional, Fahey, Michael T., additional, Roberts, Matthew J., additional, Thompson, James, additional, Murphy, Declan G., additional, Papa, Nathan, additional, Mitchell, Catherine, additional, De Abreu Lourenco, Richard, additional, Dhillon, Haryana M., additional, Kasivisvanathan, Veeru, additional, Francis, Roslyn J., additional, Stricker, Phillip, additional, Agrawal, Shihka, additional, O'Brien, Jonathan, additional, McVey, Aoife, additional, Sharma, Gaurav, additional, Levy, Sidney, additional, Ayati, Narjess, additional, Nguyen, Andrew, additional, Lee, Su-Faye, additional, Pattison, David A., additional, Sivaratnam, Dinesh, additional, Frydenberg, Mark, additional, Du, Yang, additional, Titus, Jehan, additional, Lee, Sze-Ting, additional, Ischia, Joseph, additional, Jack, Greg, additional, Hofman, Michael S., additional, and Emmett, Louise, additional

Published
2023
Full Text
View/download PDF

44. Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy

Author

Geboers, Bart, primary, Meijer, Dennie, additional, Counter, William, additional, Blazevski, Alexandar, additional, Thompson, James, additional, Doan, Paul, additional, Gondoputro, William, additional, Katelaris, Athos, additional, Haynes, Anne‐Maree, additional, Delprado, Warick, additional, O'Neill, Gordon, additional, Yuen, Carlo, additional, Vis, Andre N., additional, van Leeuwen, Pim J., additional, Ho, Bao, additional, Liu, Victor, additional, Lee, Jonathan, additional, Donswijk, Maarten L., additional, Oprea‐Lager, Daniela, additional, Scheltema, Matthijs J., additional, Emmett, Louise, additional, and Stricker, Phillip D., additional

Published
2023
Full Text
View/download PDF

45. 68Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study

Author

Gondoputro, William, primary, Doan, Paul, additional, Katelaris, Athos, additional, Scheltema, Matthijs J., additional, Geboers, Bart, additional, Agrawal, Shikha, additional, Liu, Zhixin, additional, Yaxley, John, additional, Savdie, Richard, additional, Rasiah, Kris, additional, Frydenberg, Mark, additional, Roberts, Matthew J., additional, Malouf, David, additional, Wong, David, additional, Shnier, Ron, additional, Delprado, Warick, additional, Emmett, Louise, additional, Stricker, Phillip D., additional, and Thompson, James, additional

Published
2023
Full Text
View/download PDF

47. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Author

Long, Georgina V, Saw, Robyn P M, Lo, Serigne, Nieweg, Omgo E, Shannon, Kerwin F, Gonzalez, Maria, Guminski, Alexander, Lee, Jenny H, Lee, Hansol, Ferguson, Peter M, Rawson, Robert V, Wilmott, James S, Thompson, John F, Kefford, Richard F, Ch'ng, Sydney, Stretch, Jonathan R, Emmett, Louise, Kapoor, Rony, Rizos, Helen, Spillane, Andrew J, Scolyer, Richard A, and Menzies, Alexander M

Published
2019
Full Text
View/download PDF

48. Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

Author

Emmett, Louise, Crumbaker, Megan, Ho, Bao, Willowson, Kathy, Eu, Peter, Ratnayake, Lalith, Epstein, Richard, Blanksby, Ashley, Horvath, Lisa, Guminski, Alex, Mahon, Kate, Gedye, Craig, Yin, Charlotte, Stricker, Phillip, and Joshua, Anthony M.

Published
2019
Full Text
View/download PDF

50. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.

Author

Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, and Ramdave, Shakher

Subjects
*CASTRATION-resistant prostate cancer, *OVERALL survival, *CABAZITAXEL, *SURVIVAL rate, *POSITRON emission tomography, *PROSTATE-specific antigen
Abstract

The TheraP study reported improved prostate-specific antigen responses with lutetium-177 [177Lu]Lu-PSMA-617 versus cabazitaxel in men with metastatic castration-resistant prostate cancer progressing after docetaxel. In this Article, we report the secondary outcome of overall survival with mature follow-up, and an updated imaging biomarker analysis. We also report the outcomes of participants excluded due to ineligibility on gallium-68 [68Ga]Ga-PSMA-11 and 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG) PET-CT. TheraP was an open-label, randomised phase 2 trial at 11 centres in Australia. Eligible participants had metastatic castration-resistant prostate cancer progressing after docetaxel, and PET imaging with [68Ga]Ga-PSMA-11 and 2-[18F]FDG that showed prostate-specific membrane antigen (PSMA)-positive disease and no sites of metastatic disease with discordant 2-[18F]FDG-positive and PSMA-negative findings. Participants were randomly assigned (1:1) to treatment with [177Lu]Lu-PSMA-617 (every 6 weeks for a maximum of six cycles; starting at 8·5 GBq, decreasing by 0.5 GBq to 6·0 GBq for the sixth cycle) versus cabazitaxel (20 mg/m2 every 3 weeks, maximum of ten cycles). Overall survival was analysed by intention-to-treat and summarised as restricted mean survival time (RMST) to account for non-proportional hazards, with a 36-month restriction time corresponding to median follow-up. This trial is registered with ClinicalTrials.gov , NCT03392428 , and is complete. 291 men were registered from Feb 6, 2018, to Sept 3, 2019; after study imaging, 200 were eligible and randomly assigned to treatment with [177Lu]Lu-PSMA-617 (n=99) or cabazitaxel (n=101). After completing study treatment, 20 (20%) participants assigned to cabazitaxel and 32 (32%) assigned to [177Lu]Lu-PSMA-617 were subsequently treated with the alternative regimen. After a median follow-up of 35·7 months (IQR 31·1 to 39·2), 77 (78%) participants had died in the [177Lu]Lu-PSMA-617 group and 70 (69%) participants had died in the cabazitaxel group. Overall survival was similar among those assigned to [177Lu]Lu-PSMA-617 versus those assigned to cabazitaxel (RMST 19·1 months [95% CI 16·9 to 21·4] vs 19·6 months [17·4 to 21·8]; difference –0·5 months [95% CI –3·7 to 2·7]; p=0·77). No additional safety signals were identified with the longer follow-up in this analysis. 80 (27%) of 291 men who were registered after initial eligibility screening were excluded after [68Ga]Ga-PSMA-11 and 2-[18F]FDG PET. In the 61 of these men with follow-up available, RMST was 11·0 months (95% CI 9·0 to 13·1). These results support the use of [177Lu]Lu-PSMA-617 as an alternative to cabazitaxel for PSMA-positive metastatic castration-resistant prostate cancer progressing after docetaxel. We did not find evidence that overall survival differed between the randomised groups. Median overall survival was shorter for men who were excluded because of low PSMA expression or 2-[18F]FDG-discordant disease. Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Prostate Cancer Foundation of Australia, Endocyte (a Novartis company), Australian Nuclear Science and Technology Organization, Movember, It's a Bloke Thing, CAN4CANCER, and The Distinguished Gentleman's Ride. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results